Geoffrey Duyk, MD, PhD, is Managing Director of TPG Ventures, a venture capital firm that is an affiliate of Texas Pacific Group. Previously, Dr. Duyk was President of Research & Development, and served on the Board of Directors, at Exelixis.  

Prior to Exelixis, Dr. Duyk was Vice President of Genomics at Millennium Pharmaceuticals, where he was responsible for building and leading the informatics, automation, DNA sequencing, and genotyping groups, as well as the mouse and human genetics group. Prior to Millennium Pharmaceuticals, he was an Assistant Professor at Harvard Medical School and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk was also a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center.  

Dr. Duyk is currently and previously a member of numerous NIH panels and oversight committees focused on the planning and execution of the human genome project. He is on the Board of Directors of Guava Technologies.  

Dr. Duyk holds a PhD and MD from Case Western Reserve University, and completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.